LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

Julie R. Brahmer, Delvys Rodríguez‐Abreu, AE Robinson, Rina Hui, Tibor Csőszi, András Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Ticiana Leal, Jonathan W. Riess, E. Jensen, Bin Zhao, M. Catherine Pietanza, Martin Reck